Less is More: Targeted Surgery for Thyroid Cancer Offers Hope for Reduced Complications
A new study suggests that patients with low-risk thyroid isthmus papillary cancer may benefit from a less invasive surgical approach, potentially avoiding the complications and long-term hormone dependence associated with more extensive procedures. Published recently in the Journal of the American Thyroid Association (THYROID), the research indicates that removing only the isthmus – the central region of the thyroid gland where the cancer is located – yields similar recurrence rates to removing the entire gland or a lobe, while significantly reducing post-operative burdens.
Understanding Thyroid Isthmus Papillary Cancer
Papillary thyroid cancer is the most common form of malignant thyroid tumor. While most cases develop in the left and right lobes of the thyroid, a smaller percentage – less than 10% – occur in the isthmus. Historically, surgical guidelines for these cancers have been unclear, leading to variations in treatment approaches ranging from total thyroid resection to lobectomy, or isthmus resection alone. This lack of consensus stems from the understanding that thyroid isthmus papillary cancer is often associated with multiple lesions, invasion of surrounding tissues, and lymph node metastasis.
A New Approach to Surgical Precision
Researchers at Seoul National University Hospital, led by Professor Seungho Lee and colleagues (Professors Soojin Kim and Junyoung Choi), retrospectively analyzed data from 170 patients diagnosed with low-risk thyroid isthmus papillary cancer between 2013 and 2022. Patients were categorized into three groups: those undergoing total resection, lobectomy, and isthmusectomy. Using a 1:1 propensity score matching method – accounting for factors like age, tumor size, and clinical characteristics – the team compared outcomes over a median follow-up period of 4.3 years.
The results revealed a striking difference in complication rates. Major surgical complications, including temporary and permanent hypocalcemia, and temporary vocal fold paralysis, occurred only in the total resection and lobectomy groups. Notably, these complications were entirely absent in the isthmusectomy group. The average hospitalization duration remained consistent across all groups, at approximately four days.
Reduced Hormone Dependence and Improved Quality of Life
Beyond fewer complications, patients who underwent isthmusectomy experienced significantly lower rates of post-operative dependence on thyroid hormones. Only 34.1% of the isthmusectomy group required thyroid hormone replacement therapy, compared to 90.6% in the total resection/lobectomy groups. Furthermore, the isthmusectomy group used lower doses of hormones for a shorter duration.
“This study expands the options of customized surgical strategies according to the risk of individual patients and suggests the possibility of lowering the risk of complications by reducing unnecessary extensive surgery,” stated Professor Lee.
Oncological Safety and Future Considerations
Crucially, the study found no significant difference in recurrence rates or distant metastasis between the three surgical approaches during the follow-up period. The incidence of high-risk lymph node metastasis was also comparable across groups, confirming that isthmusectomy does not compromise oncological safety when applied to appropriately selected patients.
While the isthmusectomy group did exhibit a higher incidence of new thyroid nodules, the rate of high-risk nodules – those with a greater potential for malignancy – was not significantly different from the other groups. Researchers acknowledge the need for longer-term follow-up to monitor the progression of these newly discovered nodules.
Identifying Ideal Candidates for Isthmusectomy
Based on their findings, Professor Lee’s team proposes that isthmusectomy could be considered for carefully selected patients with low-risk thyroid isthmus papillary cancer who meet specific criteria: a single lesion less than 2 cm in size, no evidence of lymph node or thyroid capsule invasion, no aggressive findings on ultrasound, and a low-risk cytological profile.
However, Professor Lee cautioned that the retrospective nature of the study and the limited follow-up period necessitate further investigation. “The limitations of the retrospective study design and follow-up period must be considered, and surgical standards need to be refined through long-term prospective studies.”
